169 related articles for article (PubMed ID: 36841305)
1. Association between depression and metabolic dysfunction-associated fatty liver disease/significant fibrosis.
Kim D; Dennis BB; Cholankeril G; Ahmed A
J Affect Disord; 2023 May; 329():184-191. PubMed ID: 36841305
[TBL] [Abstract][Full Text] [Related]
2. Associations of depression score with metabolic dysfunction-associated fatty liver disease and liver fibrosis.
Cai H; Zhang R; Zhao C; Wang Y; Tu X; Duan W
J Affect Disord; 2023 Aug; 334():332-336. PubMed ID: 37142003
[TBL] [Abstract][Full Text] [Related]
3. Sex- and region-specific associations of skeletal muscle mass with metabolic dysfunction-associated fatty liver disease.
Xiao P; Liang P; Gao P; Wu J
Front Endocrinol (Lausanne); 2022; 13():1057261. PubMed ID: 36531457
[TBL] [Abstract][Full Text] [Related]
4. Impact of the new definition of metabolic dysfunction-associated fatty liver disease on detection of significant liver fibrosis in US adolescents.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Hepatol Commun; 2022 Aug; 6(8):2070-2078. PubMed ID: 35470984
[TBL] [Abstract][Full Text] [Related]
5. MAFLD and risk of CKD.
Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
[TBL] [Abstract][Full Text] [Related]
6. Associations of Serum Iron Status with MAFLD and Liver Fibrosis in the USA: a Nationwide Cross-Section Study.
Yu G; Liu L; Qin T; Luo Y; Song C; Chen X; Duan H; Jiang Y; Zeng H; Wan H; Shen J
Biol Trace Elem Res; 2024 Jan; 202(1):87-98. PubMed ID: 37079265
[TBL] [Abstract][Full Text] [Related]
7. Depression is associated with non-alcoholic fatty liver disease among adults in the United States.
Kim D; Yoo ER; Li AA; Tighe SP; Cholankeril G; Harrison SA; Ahmed A
Aliment Pharmacol Ther; 2019 Sep; 50(5):590-598. PubMed ID: 31328300
[TBL] [Abstract][Full Text] [Related]
8. The association of triglyceride-glucose-waist circumference with metabolic associated fatty liver disease and the severity of liver steatosis and fibrosis in American adults: a population-based study.
Wu Z; Huang K; Bao S; Zhang X; Li J; Kong W; Shi Y; Xie Y
Scand J Gastroenterol; 2024 May; 59(5):561-569. PubMed ID: 38235548
[TBL] [Abstract][Full Text] [Related]
9. Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population.
Yang S; Cheng J; Zhang R; Sun H; Zhang H; Lyu S; Duan W
Hepatol Res; 2022 Feb; 52(2):176-186. PubMed ID: 34751487
[TBL] [Abstract][Full Text] [Related]
10. Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease.
Chun HS; Kim MN; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU
J Cachexia Sarcopenia Muscle; 2021 Oct; 12(5):1168-1178. PubMed ID: 34337887
[TBL] [Abstract][Full Text] [Related]
11. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population.
Seo JY; Cho EJ; Kim MJ; Kwak MS; Yang JI; Chung SJ; Yim JY; Yoon JW; Chung GE
J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):2953-2960. PubMed ID: 36222309
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
Liu D; Shen Y; Zhang R; Xun J; Wang J; Liu L; Steinhart C; Chen J; Lu H
J Gastroenterol Hepatol; 2021 Jun; 36(6):1670-1678. PubMed ID: 33140878
[TBL] [Abstract][Full Text] [Related]
13. The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations.
Feng Z; Zhao F; Wang Z; Tang X; Xie Y; Qiu L
BMC Gastroenterol; 2024 Mar; 24(1):111. PubMed ID: 38491346
[TBL] [Abstract][Full Text] [Related]
14. Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease.
Han E; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Kim SU
Gut Liver; 2022 Sep; 16(5):786-797. PubMed ID: 35321955
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population.
Ciardullo S; Perseghin G
Liver Int; 2021 Jun; 41(6):1290-1293. PubMed ID: 33590934
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV-positive people.
Jongraksak T; Sobhonslidsuk A; Jatchavala J; Warodomwichit D; Kaewduang P; Sungkanuparph S
Int J STD AIDS; 2021 Mar; 32(3):266-275. PubMed ID: 33334267
[TBL] [Abstract][Full Text] [Related]
17. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
Hu Q; Chen Y; Bao T; Huang Y
Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
[TBL] [Abstract][Full Text] [Related]
18. Association of low muscle strength with metabolic dysfunction-associated fatty liver disease: A nationwide study.
Lee GB; Huh Y; Lee SH; Han B; Kim YH; Kim DH; Kim SM; Choi YS; Cho KH; Nam GE
World J Gastroenterol; 2023 Dec; 29(45):5962-5973. PubMed ID: 38131000
[TBL] [Abstract][Full Text] [Related]
19. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
[TBL] [Abstract][Full Text] [Related]
20. Association between self-reported snoring and metabolic-associated fatty liver disease: A cross-sectional analysis of the NHANES 2017-2018.
Wang Y; Shen R; Ge J
Sleep Med; 2023 Jan; 101():414-420. PubMed ID: 36516525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
